about
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a colla...
Read More
136.19
-0.53
(-0.39%)
346.7K
XNAS Volume
XNAS 27 Aug, 2025 11:51 AM (EDT)
High Financial Strength
Affordable Valuation
Technically Neutral
Strong Performer, Under Radar
These stocks are with good quality scores and with strong financials. They are affordably priced stocks and can give good returns
View Similar
Embed DVM
Biogen Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..